Join to View Full Profile
550 1st AveNew York, NY 10016
Phone+1 212-686-7500
Dr. Rappo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Infectious Disease, 2009 - 2011
NYU Grossman School of MedicineResidency, Internal Medicine, 2006 - 2009
Drexel University College of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2009 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Start of enrollment: 2016 Mar 15
- Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis Start of enrollment: 2017 May 12
Publications & Presentations
PubMed
- 4 citationsDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical...Todd Riccobene, John Lock, Rosie D Lyles, Benjamin Georgiades, Michael Nowak
Open Forum Infectious Diseases. 2023-06-01 - 250 citationsTargeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.Sara Federici, Sharon Kredo-Russo, Rafael Valdés-Mas, Denise Kviatcovsky, Eyal Weinstock
Cell. 2022-08-04 - 26 citationsDalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.Nicholas A Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki
Trials. 2022-05-16
Press Mentions
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis ConferenceSeptember 18th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
